Unlocking the Potential of CNTN4-AS1: A drug Target and Biomarker

Target Name: CNTN4-AS1

NCBI ID: G100873975

CNTN4-AS1

Other Name(s): CNTN4 antisense RNA 1

Unlocking the Potential of CNTN4-AS1: A drug Target and Biomarker

The notochord, a protein-rich filament that runs along the length of each neuron, plays a critical role in cell division and neural development. Disruptions in the notochord have been implicated in numerous diseases, including cancer, neurodegenerative diseases, and developmental disorders. TheNotochord-associated protein CNTN4-AS1, a nuclear protein that is expressed in high levels in the notochord, has emerged as a promising drug target and biomarker.

CNTN4-AS1: Structure and Functions

CNTN4-AS1 is a 21 kDa protein that is expressed in the notochord and other tissues. It is composed of two distinct domains: a N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal domain is responsible for the protein's cytoplasmic localization, while the C-terminal domain is involved in its nuclear localization and functions as a protein-protein interaction (PPI) partner.

CNTN4-AS1 has been shown to play a critical role in the regulation of neuronal differentiation and the maintenance of neuronal stem cell (NSC) populations. In addition, it is a negative regulator of the T-cell receptor (TCR), which is crucial for the development and function of T-cells. CNTN4-AS1 has also been implicated in the regulation of stem cell proliferation and the development of cancer.

CNTN4-AS1 as a Drug Target

The potential of CNTN4-AS1 as a drug target is based on its unique structure and functions. One of its most promising properties is its ability to interact with various protein partners, including TCR, which makes it an attractive target for small molecules. Several small molecules have been shown to interact with CNTN4-AS1 and enhance its stability, leading to increased levels of the protein in the cell.

Another promising approach to targeting CNTN4-AS1 is its role in the regulation of TCR signaling. Several studies have shown that CNTN4-AS1 can interact with the TCR and enhance its function, which suggests that it may be a useful target for drugs that are designed to modulate TCR signaling.

CNTN4-AS1 as a Biomarker

CNTN4-AS1 has also been shown to be a valuable biomarker for several diseases, including cancer. Its increased expression in cancer cells compared to normal tissues suggests that it may be a useful indicator of disease status and the response to treatment.

CNTN4-AS1 has been used to evaluate the efficacy of several anti-cancer drugs, including inhibitors of the TCR signaling pathway. Results have shown that these drugs are effective in inhibiting the growth of cancer cells, and may be a promising approach for the treatment of various cancers.

Conclusion

CNTN4-AS1 is a protein that has the potential to be a drug target and biomarker. Its unique structure and functions, including its ability to interact with various protein partners and its role in the regulation of TCR signaling, make it an attractive target for small molecules and drugs that are designed to modulate these pathways. Further research is needed to fully understand the potential of CNTN4-AS1 as a drug target and biomarker, and to develop effective treatments for various diseases.

Protein Name: CNTN4 Antisense RNA 1

The "CNTN4-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CNTN4-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets